Remeditex Ventures

Managing Directors Dennis Gorman and Maxim Kholin jointly lead the firm's investment operations. Both were instrumental in architecting the academic-origination model that defines Remeditex's deal flow. The partnership structure is deliberately flat, with the principals directly involved in sourcing, structuring, and board-level governance of portfolio companies.

Remeditex derives its pipeline from embedded partnerships with major academic research institutions. Rather than participating in broad auction processes, the firm identifies promising biomedical intellectual property inside university labs, forms a new company around the licensed asset, and leads the initial financing. This origination model gives the firm founder-level equity access and significant influence over clinical and corporate strategy.

Remeditex concentrates on direct equity positions in the companies it co-founds and leads. The firm does not market itself as a fund-of-funds investor, preferring concentrated, board-level commitments within its area of biomedical specialization. Co-investment syndicates typically include life-science-dedicated venture funds and occasionally strategic pharmaceutical partners.

The firm operates from the pre-incorporation stage — forming the company around university-originated intellectual property — through Series A and expansion rounds. Its timeline is tied to drug and device development milestones rather than fixed fund-life constraints, allowing Remeditex to support assets through regulatory filing and clinical inflection points.

Most platform biotech funds invest as participants in syndicated Series A and B rounds across dozens of external deals. Remeditex operates further upstream, acting as a company builder and the lead institutional investor in the assets it creates from academic research. This yields a smaller, more concentrated portfolio and a partnership economics structure that differs from a standard 2-and-20 commingled venture fund.